New guideline recommendations prefer direct oral anticoagulants (DOACs) over warfarin in
DOAC-eligible patients with atrial fibrillation and patients with venous thromboembolism. As …

Background Idarucizumab has been approved to reverse the anticoagulant effect of
dabigatran. However, there is little knowledge of the effectiveness and safety of …

Abstract Editor's Perspective What We Already Know about This Topic Measuring the effects
of factor Xa inhibitor levels to guide the management of patients needing urgent surgery or …

Introduction Direct thrombin inhibitor, dabigatran and factor Xa inhibitors, apixaban,
edoxaban, and rivaroxaban (DOACs/NOACs), are currently the first-choice drugs in some …

Introduction: Dabigatran, a direct thrombin inhibitor, is 80% renally eliminated and
demonstrates multi-compartmental pharmacokinetics. Idarucizumab is a monoclonal …

Introduction Trauma care providers are facing an increasing number of elderly patients on
direct oral anticoagulants prior to injury. For dabigatran etexilate (DAB), the specific …

门静脉血栓(portal vein thrombosis, PVT) 是肝硬化的常见并发症之一, 可使门静脉压力进一步
升高, 加重肝功能失代偿; 但由于起病隐匿, 症状不典型, 其重要性在临床诊疗工作中长期被忽视 …

心房颤动患者常口服抗凝药预防静脉血栓栓塞和脑卒中的同时也会增加出血的风险. 本文报告1
例临床药师参与达比加群酯治疗非瓣膜性房颤患者致脑出血后, 紧急使用依达赛珠单抗逆转的 …

To reverse anticoagulation in the hemorrhaging patient, specific antidotes should be the first
option if available, followed by four-factor prothrombin complex concentrate (PCC), activated …

新型口服抗凝药可用于心房颤动患者的卒中预防和静脉血栓栓塞性疾病的治疗. 与维生素K
拮抗剂相比, 新型口服抗凝药的相关出血事件较少, 但当出血发生时, 医生评估和管理新型口服抗 …